The primary RNA transcript of the calcitonin (CT) gene is alternatively processed. In C-cells, the primary transcript is processed by polyadenylation after the 4th exon with constitutive splicing of exons 1 through 4. Processing in neuronal cells results in polyadenylation at the end of exon 6 and skipping of exon 4 to produce a five-exon mRNA (exons 1,2,3,5 and 6) encoding for calcitonin gene-related peptide (CGRP). A minigene construct consisting of the first adenovirus exon fused to exons 3, 4, and 5 and of the CT gene is processed in a CT-specific pattern by HeLa cells and in a """"""""skip"""""""" or CGRP-specific pattern in F9 teratocarcinoma cells. We used this truncated construct to develop an in vitro RNA processing system. In the in vitro model system, nuclear extract from F9 cell line processed RNA derived from the CT minigene construct in a CGRP- specific pattern. Nuclear extracts the HeLa cell line processed the same construct by recognizing and polyadenylating after exon 4, but did not remove the intron immediately preceding the CT exon. We determined this failure to remove intron 3 was caused by a weak 3' CT branch/splice site; a single base mutation at the CT 3' branch point resulted in production of a CT-specific splice in the HeLa cell system and a correct cell-specific splice when processed in the F9 system. Complementation of HeLa extract with F9 extract produced a CGRP-specific splice, indicating the presence of a dominant factor in the F9 nuclear extract. Studies in the in vitro system have defined 2 regions of regulatory significance: first, the terminal portion of intron 3 (the intron preceding the calcitonin exon); and second, a 10 bp sequence in the proximal 4th (CT) exon. In preliminary studies we have identified a 66 kK protein (exon binding protein) which binds to the exon 4 sequence. We hypothesize the presence of an F9 factor which interacts at the 3' CT branch/splice or within exon 4 to prevent binding of the exon binding protein thereby causing a """"""""skip"""""""" splice. We propose further mapping of these regulatory regions and utilization of this in vitro system to purify, sequence and clone the exon binding protein and putative F9 factor. Purification of the exon binding protein will be monitored by its specific crosslinking to the 10 nucleotide exon 4 sequence. Purification of the F9 factor will be monitored by its dominant ability to switch the pattern of splicing from a CT to a CGRP pattern or by its ability to prevent crosslinking of the exon binding protein to the 10 nucleotide exon 4 sequence.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
2R01DK038146-03A2
Application #
3237376
Study Section
Endocrinology Study Section (END)
Project Start
1988-09-20
Project End
1996-02-28
Budget Start
1992-03-27
Budget End
1993-02-28
Support Year
3
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Lou, H; Gagel, R F (2001) Alternative ribonucleic acid processing in endocrine systems. Endocr Rev 22:205-25
Hoff, A O; Cote, G J; Fritsche Jr, H A et al. (1999) Calcium-induced activation of a mutant G-protein-coupled receptor causes in vitro transformation of NIH/3T3 cells. Neoplasia 1:485-91
Lou, H; Helfman, D M; Gagel, R F et al. (1999) Polypyrimidine tract-binding protein positively regulates inclusion of an alternative 3'-terminal exon. Mol Cell Biol 19:78-85
Lou, H; Gagel, R F (1998) Alternative RNA processing--its role in regulating expression of calcitonin/calcitonin gene-related peptide. J Endocrinol 156:401-5
Lou, H; Neugebauer, K M; Gagel, R F et al. (1998) Regulation of alternative polyadenylation by U1 snRNPs and SRp20. Mol Cell Biol 18:4977-85
Thomas, P M; Wohllk, N; Huang, E et al. (1996) Inactivation of the first nucleotide-binding fold of the sulfonylurea receptor, and familial persistent hyperinsulinemic hypoglycemia of infancy. Am J Hum Genet 59:510-8
Wohllk, N; Cote, G J; Bugalho, M M et al. (1996) Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81:3740-5
Lou, H; Gagel, R F; Berget, S M (1996) An intron enhancer recognized by splicing factors activates polyadenylation. Genes Dev 10:208-19
Lou, H; Yang, Y; Cote, G J et al. (1995) An intron enhancer containing a 5' splice site sequence in the human calcitonin/calcitonin gene-related peptide gene. Mol Cell Biol 15:7135-42
Thomas, P M; Cote, G J; Wohllk, N et al. (1995) Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 268:426-9

Showing the most recent 10 out of 20 publications